CommercialPfizer and Starna Therapeutics Sign an Exclusive Licensing Contract...

Pfizer and Starna Therapeutics Sign an Exclusive Licensing Contract for Autoimmune Conditions

-

Pfizer Inc. announced that it has entered into an exclusive collaboration with Starna Therapeutics, a biotechnology company focused on the development of RNA medicines for in vivo therapeutics. Under the agreement, Pfizer obtains exclusive rights outside Greater China to develop, manufacture, and commercialize three pre-IND in vivo chimeric antigen receptor T-cell (CAR-T) programs that are focused on treating autoimmune diseases. Pfizer also gains the rights to use Starna’s proprietary in vivo CAR-T technology in inflammation & immunology and oncology, receives options to exclusively license compounds developed under a separate research collaboration, and an option to expand the territory to include exclusive rights to develop and commercialize each exclusively licensed compound and product in the Greater China region.

The patients who might benefit most are those for whom current therapies cannot help, and we are very familiar with the RNA medicines development and manufacturing process at Pfizer, so the in vivo CAR-T programs and technology from Starna are an exciting opportunity for us to explore. Michael Vincent, Chief Inflammation & Immunology Officer, Pfizer

We believe that our vision of unlocking the potential of RNA medicines to improve patient care will form a solid base to realize our in vivo CAR-T therapies, and we are excited to collaborate with Pfizer, a global leader in drug development, to introduce transformative therapies to patients around the world. Rongkuan Hu, President & CEO, Starna Therapeutics

Enabling Promising Science for Patients

Today’s agreement broadens Pfizer’s Inflammation & Immunology pipeline and enables Pfizer to deploy its extensive scientific expertise in RNA delivery and specialization in immunology research, clinical development, and commercialization to a promising, next-generation approach in cell therapy. Starna’s innovative technology opens new opportunities for the design of potentially transformative autoimmune and cancer treatments in the future.

About Pfizer: Breakthroughs That Change Patients’ Lives

At Pfizer, we use science and our resources worldwide to provide therapies to people that extend and greatly enhance their lives. We aim to lead the way in the quality, safety, and value of health care products we discover, develop, and manufacture, such as innovative medicines and vaccines. Pfizer employees strive each day to improve wellness, prevention, treatments and cures in both developed and emerging markets to combat the most threatening diseases of today. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 175 years, we have strived to make a difference for all who depend on us. Periodically, we update information that could be of interest to investors on our Internet site at www.Pfizer.com.

Pfizer and Starna Therapeutics Enter a Major Autoimmune Deal

Starna Therapeutics has entered an exclusive licensing agreement with Pfizer to advance three experimental in vivo CAR-T cell therapy programs targeting autoimmune diseases. Announced on November 18, 2026, the agreement gives Pfizer exclusive rights to develop, manufacture and commercialize the licensed programs outside Greater China.

1. Starna Therapeutics Gives Pfizer Access to Three CAR-T Programs

The agreement covers three preclinical, pre-investigational new drug (pre-IND) in vivo chimeric antigen receptor T-cell (CAR-T) programs developed by Starna Therapeutics.

These experimental therapies are designed to treat autoimmune diseases by modifying immune cells inside a patient’s body. The programs are still at an early stage and have not yet entered human clinical trials.

Through the agreement, Pfizer gains the opportunity to advance these programs using its experience in drug development, clinical research, manufacturing and global commercialization.

The companies have not publicly disclosed the specific molecular targets or autoimmune disease indications for the three programs.

2. Starna Therapeutics Deal Could Reach $2.63 Billion

The financial terms make this agreement one of the significant biotechnology licensing transactions announced in November 2026.

The agreement includes:

  • Upfront payment: $330 million to Starna Therapeutics.

  • Potential milestones: Up to $2.3 billion tied to development and commercial achievements.

  • Royalties: Additional payments based on net sales of approved products.

  • Development responsibility: Pfizer will lead clinical development outside Greater China.

  • Manufacturing: Pfizer plans to manufacture initial clinical-trial supplies at its facilities in the United States.

  • Commercialization: Pfizer will control commercialization outside Greater China.

The potential total of upfront and milestone payments is approximately $2.63 billion, excluding royalties. These additional payments depend on the achievement of specified milestones rather than being guaranteed.

Pfizer+1

3. Starna Therapeutics Advances In Vivo CAR-T Technology

Traditional CAR-T treatments generally involve collecting a patient’s immune cells, genetically modifying them in a specialized manufacturing facility and returning the modified cells to the patient.

This process can be complex, time-consuming and expensive.

In vivo CAR-T technology takes a different approach. Instead of modifying cells outside the body, it aims to deliver genetic instructions directly into the patient’s body so that selected immune cells can be reprogrammed internally.

Latest news

Top 10 Risks Associated With Pharmaceutical Raw Material Sourcing

Executive Summary Pharmaceutical raw material sourcing directly influences product quality, manufacturing continuity, regulatory compliance, and commercial performance. Active pharmaceutical ingredients...

Bristol Myers Squibb Combines Research and Development Under Cristian Massacesi

Bristol Myers Squibb (BMS) will consolidate its research and development operations into a single organization under the leadership of...

Regeneron reports encouraging phase 2 results for baloncibart in a crucial trial for nervous system disorders and eyes

Regeneron has posted positive phase 2 data on baloncibart in postural orthostatic tachycardia syndrome (POTS), teeing the biotech up...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you